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Myotonic dystrophy type 1 and type 2 (DM1, DM2) are caused by expansions of CTG and
CCTG repeats, respectively. RNAs containing expanded CUG or CCUG repeats interfere with
the metabolism of other RNAs through titration of the Muscleblind-like (MBNL) RNA binding
proteins. DM2 follows a more favorable clinical course than DM1, suggesting that speciﬁc
modiﬁers may modulate DM severity. Here, we report that the rbFOX1 RNA binding protein
binds to expanded CCUG RNA repeats, but not to expanded CUG RNA repeats. Interestingly,
rbFOX1 competes with MBNL1 for binding to CCUG expanded repeats and overexpression of
rbFOX1 partly releases MBNL1 from sequestration within CCUG RNA foci in DM2 muscle
cells. Furthermore, expression of rbFOX1 corrects alternative splicing alterations and rescues
muscle atrophy, climbing and ﬂying defects caused by expression of expanded CCUG repeats
in a Drosophila model of DM2.
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Myotonic dystrophy is the most common muscular dys-trophy in adults and comprises two genetically distinctforms. Myotonic dystrophy type 1 (DM1) and its severe
congenital form (CDM1) are caused by an expansion of
CTG repeats in the 3′-untranslated region (UTR) of the DMPK
gene1–3. In contrast, myotonic dystrophy type 2 (DM2) is caused
by an expansion of CCTG repeats within the ﬁrst intron of the
CNBP (also known as ZNF9) gene4. Expression of mutant RNAs
containing hundreds to thousands of CUG or CCUG repeats
interferes with the metabolism of other RNAs through dysfunc-
tions of mainly two classes of RNA binding proteins. First,
expression and phosphorylation of the CUG-binding protein 1
(CUGBP1, encoded by the CELF1 gene) are increased in DM1
heart samples, especially in the most severely affected indivi-
duals5. Second, Muscleblind-like proteins (MBNL1, MBNL2 and
MBNL3), which are RNA binding proteins speciﬁcally recogniz-
ing YGC RNA motifs, are titrated away from their normal mRNA
targets as a result of their binding to expanded CUG and CCUG
RNA repeats. MBNL proteins titration is illustrated by their
mislocalization within nuclear RNA foci formed by expanded
CUG and CCUG repeats in cell and animal models of myotonic
dystrophy6–8. MBNL and CUGBP1 are RNA binding proteins
that regulate pre-mRNA alternative splicing9–14. Thus, alterations
of MBNL and CUGBP1 functional levels result in reversion to
embryonic splicing patterns for various mRNAs, which are
associated with several symptoms of myotonic dystrophy15–22.
Importantly, knockout of Mbnl1 and/ or Mbnl2 in mouse
reproduces splicing alterations and keys features of myotonic
dystrophy10,13,14,20,23. Conversely, overexpression of MBNL1
corrects splicing alterations and myotonia in mice expressing
expanded CUG repeats24. Finally, a higher number of pathogenic
CUG repeats leads to a greater titration of MBNL proteins,
resulting in increased RNA metabolism alterations that correlate
with increased disease severity in DM1 individuals23,25. These
results highlight the importance of MBNL titration in myotonic
dystrophy type 1.
Myotonic dystrophy type 2 resembles adult-onset DM1 with
autosomal dominant inheritance pattern and similar clinical
multi-organ features, including progressive skeletal muscle atro-
phy and weakness, myotonia, cardiac arrhythmia and conduction
defects, posterior subcapsular iridescent cataract, insulin resis-
tance, hypogammaglobulinemia, as well as cognitive and per-
sonality changes26–28. Despite these similarities, there are
signiﬁcant differences between DM1 and DM2, including a
usually more favorable clinical course in DM2 compared to DM1.
Indeed, symptoms are generally milder in DM2 compared to
DM1 and include slower and less severe progression of the dis-
ease, reduced severity of the cardiac involvement, later and less
prominent weakness of the respiratory, facial and bulbar muscles,
less evocable myotonia and preserved social and cognitive abil-
ities29–31. A milder involvement in DM2 compared to DM1 is
also found at the cellular level as in vitro cultures of muscle cells
originating from individuals with DM1 reveal reduced fusion
capacity and alternative splicing alterations compared to control
cells. However, only subtle or even no detectable fusion defects
or splicing alterations are observed in cultures of DM2 myo-
blasts32–34. Paradoxically, these milder clinical and cellular fea-
tures are in contradiction with the 3 to 5 folds higher expression
of the CNBP mRNA, which ﬁrst intron hosts the expanded
CCUG repeat, compared to the DMPK mRNA, which 3’UTR
hosts the expanded CUG repeats7,35,36. Furthermore, the average
size of expanded repeats is generally higher in DM2 (up to
~11,000 CCTG repeats in blood) compared to adult-onset DM1
(up to ~1000 CTG repeats in blood)4. Thus, expanded CCUG
repeats appear inherently less pathogenic than expanded CUG
repeats. A likely contribution to this difference of toxicity is their
genomic localization as CCUG repeats are embedded in the ﬁrst
intron of the CNBP pre-mRNA, which is presumably less stable
compared to the 3′UTR of the DMPK mRNA that hosts the CUG
repeats. In favor of this hypothesis, transgenic Drosophila
expressing either expanded CUG or CCUG repeats, embedded in
a comparable genomic context deprived of any DMPK or CNBP
sequences, show similar DM-like phenotypes37,38. Nonetheless, it
is not excluded that other mechanisms may further contribute to
the lesser toxicity of expanded CCUG repeats in DM2.
Searching for novel RNA binding proteins that interact spe-
ciﬁcally with either CUG or CCUG expanded repeats, we iden-
tiﬁed that the rbFOX RNA binding proteins bind to expanded
CCUG repeats, but not to expanded CUG repeats. The rbFOX
family comprises three members, rbFOX1 (also named Fox-1,
A2BP1 or HRNBP1), rbFOX2 (also known as Fox-2, RBM9, Fxh
or HRNBP2) and rbFOX3 (also called Fox-3, NeuN or HRNBP3),
which are involved in the regulation of various aspects of mRNA
metabolism39–47. While rbFOX2 is widely expressed, rbFOX1 is
enriched in skeletal muscle, heart and brain, and rbFOX3
expression is restricted to neuronal cells48. All three rbFOX
proteins possess a near-identical RNA-recognition motif (RRM)
that recognizes the UGCAUGY RNA sequence39–41,49.
Here, we ﬁnd that rbFOX1 also binds to expanded CCUG
repeats, albeit with a lesser afﬁnity compared to its favorite
UGCAUGY sequence. Interestingly, rbFOX1 co-localizes with
CCUG RNA foci in muscle cells and skeletal muscle tissues of
individuals with DM2. In contrast, rbFOX1 does not bind to
expanded CUG repeats and does not co-localize with CUG RNA
foci in DM1 samples. Furthermore, we ﬁnd that the binding of
MBNL1 and rbFOX1 to expanded CCUG repeats are mutually
exclusive. Addition of rbFOX1 competes with MBNL1 binding to
CCUG repeats and partially releases MBNL1 from CCUG RNA
foci in DM2 muscle cells. Importantly, expression of rbFOX1
corrects splicing alterations and reduces muscle atrophy, as well
as climbing and ﬂying defects caused by expression of expanded
CCUG repeats in Drosophila models of DM2. Thus, we propose
that the rbFOX proteins, by competing with and reducing the
titration of MBNL1 within CCUG RNA foci, may participate to
the lesser toxicity of the CCTG repeat expansion in myotonic
dystrophy type 2.
Results
Identiﬁcation of proteins associated with expanded CCUG
repeats. To identify novel RNA binding proteins involved in
myotonic dystrophy, we incubated radioactively labeled CUG or
CCUG RNA repeats with nuclear extract of differentiated mouse
C2C12 muscle cells and analyzed the RNA-bound proteins by
UV-light crosslink followed by SDS page gel electrophoresis
(Fig. 1a). Consistent with the pioneering work of the Swanson
group6, a UV-crosslink signal around 42 to 45 kDa, which cor-
responds to Mbnl1 molecular weight, was evident for both CUG
and CCUG RNAs. In contrast, a signal at 35 to 40 kDa was
observed only with CCUG RNA repeats (Fig. 1a). To identify this
factor, proteins from differentiated C2C12 muscle cells were
captured on streptavidin resin coupled to biotinylated RNA
composed of thirty CUG or CCUG repeats, eluted, separated on
SDS–PAGE gels, silver stained and each protein band was cut, gel
extracted and proteins were identiﬁed by nanoLC/MS-MS ana-
lysis (Supplementary Table 1). Mass spectrometry revealed that
the band of ~35 to 40 kDa contains various proteins, including
Tra2a (33 kDa), Pcbp1 and Pcbp2 (37 and 38 kDa), Hnrnpa3 (40
kDa), Tiar (43 kDa) and rbFox1 (38 kDa). Importantly, only
rbFox1 was preferentially associated with CCUG repeats and not
with CUG repeats (Supplementary Table 1). We repeated these
capture experiments using mouse brain nuclear extract. Silver
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staining of the captured proteins conﬁrmed that proteins of ~35
to 40 kDa were speciﬁcally pulled-down by the CCUG RNA
repeats (Fig. 1b). Gel extraction followed by mass spectrometry
analysis identiﬁed these proteins as rbFox1, rbFox2 and rbFox3
(Supplementary Table 2). Western blotting analysis of the pro-
teins eluted from the RNA afﬁnity columns conﬁrmed that
rbFox1 binds to CCUG repeats, but not to CUG repeats (Fig. 1c).
As a positive control, Mbnl1 binds to both CUG and CCUG
repeats (Fig. 1c).
To conﬁrm these results, candidate proteins identiﬁed by mass
spectrometry were tested for co-localization with RNA foci of
either expanded CUG or CCUG RNA repeats in transfected
muscle C2C12 cells. As previously reported, Mbnl1 co-localizes
with RNA foci of both expanded CUG and CCUG repeats
(Fig. 1d). In contrast, rbFox1, rbFox2, and rbFox3 co-localize only
with RNA foci of expanded CCUG repeats, but not with foci of
expanded CUG repeats (Fig. 1e and Supplementary Fig. 1). All
other tested candidate proteins do not co-localize signiﬁcantly
with CUG or CCUG RNA foci and thus were not investigated
further (Fig. 1f and Supplementary Fig. 1).
rbFOX1 directly binds to expanded CCUG repeats RNA. Pre-
sence of rbFOX1 within a large protein complex46 questions
whether rbFOX1 contacts directly CCUG RNA repeats or
requires indirect protein-protein interactions. Both gel-shift and
UV-crosslinking experiments demonstrated that puriﬁed recom-
binant GST-tagged rbFOX1 directly binds to CCUG repeats, but
not to CUG repeats (Fig. 2a and Supplementary Fig. 2A, B).
Similarly, rbFOX2, which contains a RNA-recognition motif
identical to rbFOX1, also binds to CCUG repeats, but not to CUG
repeats (Supplementary Fig. 2C). As a positive control, MBNL1
binds to both CUG and CCUG repeats (Fig. 2b and supple-
mentary Fig. 2D). Of interest, MBNL1 binds to CUG or CCUG
repeats with higher afﬁnity compared to its natural BIN1 or INSR
pre-mRNA targets (Supplementary Fig. 2E). In contrast, rbFOX1
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Fig. 1 Identiﬁcation of proteins speciﬁcally associated with expanded CCUG repeats. a UV-crosslinking binding assays of 20 µg of nuclear extract from
C2C12 muscle cells differentiated four days incubated with 30,000 CPM of uniformly [αP32] internally labeled in vitro transcribed RNAs containing 30
CUG or CCUG repeats. b Silver staining of proteins extracted from 1mg of mouse brain and captured on streptavidin resin coupled to biotinylated RNA
containing 30 CUG or CCUG repeats. c Western blotting against either rbFox1 or Mbnl1 on mouse brain proteins captured by RNA-column containing
either 30 CUG or 30 CCUG repeats. d RNA FISH against CCUG repeats coupled to immunoﬂuorescence against Mbnl1 on differentiated C2C12 cells
transfected with a plasmid expressing either 960 CUG or 1000 CCUG repeats. e RNA FISH against CCUG repeats coupled to immunoﬂuorescence against
rbFox1 on differentiated C2C12 cells transfected with a plasmid expressing either 960 CUG or 1000 CCUG repeats. Scale bars, 10 µm. Nuclei were
counterstained with DAPI. f Quantiﬁcation of the co-localization of CUG or CCUG RNA foci with candidate proteins in transfected C2C12 cells. Error bars
indicate s.e.m. of three independent experiments. Representative images are presented in Supplementary Fig. 1
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binds to ten CCUG repeats with a 2 to 5 folds lesser afﬁnity
compared to its known UGCAUGC RNA motif or to its natural
BIN1 or INSR pre-mRNA targets (Supplementary Fig. 2F).
Competition experiments conﬁrmed that rbFOX1 binds pre-
ferentially to the UGCAUGC RNA motif compared to CCUG
repeats (Supplementary Fig. 2G). Of interest, binding of rbFOX1
to two CCUG repeats (UGCCUGCC RNA sequence) is negligible
compared to the UGCAUGC sequence (Supplementary Fig. 2F),
indicating that signiﬁcant binding of rbFOX1 to the CCUG RNA
motif required repetition of that motif. Apparent KD are indicated
in the supplementary Fig. 2H.
Next, we investigated how rbFOX1 can interact, even with a
weak afﬁnity, with expanded CCUG RNA repeats. Previously
determined NMR structure of the RNA-recognition motif (RRM)
of rbFOX1 in complex with the UGCAUGU sequence shows that
the central adenosine (underlined) is not involved in any direct
RNA-protein interaction49. Strikingly, replacement of this
adenine by a cytosine yields a motif matching perfectly DM2
mutation (Fig. 2c), questioning whether rbFOX1 can accommo-
date a cytosine instead of the adenine in the UGCAUGC RNA
motif. Indeed, energy minimization and computer modeling of
rbFox1 RRM in complex with UGCCUGC RNA shows that the
substitution to a cytosine in position four allows the base to adopt
a similar base pairing with guanine two compared to the
previously shown adenine-guanine interactions (Fig. 2, e).
Importantly, we conﬁrmed this model by NMR spectroscopy,
and comparison of the amide backbone chemical shifts of both
complexes (Supplementary Fig. 2I, 2J) indicates that the number
of intra RNA hydrogen bonds is preserved and supports the
overall similar binding topology between UGCCUGC and
UGCAUGC RNAs. These results conﬁrm that rbFOX1 directly
binds to CCUG RNA repeats.
rbFOX1 co-localizes with CCUG RNA foci in DM2 patients.
We next assessed the localization of endogenous rbFOX proteins
in muscle cells and tissues of individuals with DM2. Importantly,
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RNA FISH coupled to immunoﬂuorescence analysis revealed that
endogenous rbFOX1 co-localizes with endogenous CCUG RNA
foci in primary cultures of differentiated muscle cells originating
from skeletal muscle biopsies of individuals with DM2 (Fig. 3a
and Supplementary Fig. 3A, 3B). In contrast, rbFOX1 is not
present within CUG RNA foci in DM1 muscle cells (Fig. 3a).
Concomitant labeling of endogenous MBNL1 demonstrated co-
localization of MBNL1 with both CUG and CCUG RNA foci
(Fig. 3a and Supplementary Fig. 3B). We conﬁrmed these results
in skeletal muscle sections of individuals with myotonic dystro-
phy. RNA FISH coupled to immunoﬂuorescence indicated that
both rbFOX1 and rbFOX2 co-localize with CCUG RNA foci in
DM2 muscle sections, but not with CUG RNA foci in DM1
muscle sections (Fig. 3b, c). Concomitant labeling of endogenous
MBNL1 demonstrated co-localization of MBNL1 with both CUG
and CCUG RNA foci (Fig. 3b, c). As controls, RNA FISH coupled
to immunoﬂuorescence analysis indicated that neither endogen-
ous rbFox1 nor rbFox2 co-localize with RNA foci of over-
expressed expanded CUG, CGG or AUUCU repeats, which are
involved in DM1, Fragile X Tremor and Ataxia Syndrome
(FXTAS) and spinocerebellar ataxia of type 10 (SCA10), respec-
tively (Supplementary Fig. 3C and 3D). Overall, these data indi-
cate that rbFOX1 and rbFOX2 are speciﬁc components of CCUG
RNA foci in myotonic dystrophy type 2.
rbFOX splicing regulatory functions are not altered in DM2.
To test a potential titration of rbFOX1 within CCUG RNA foci,
we ﬁrst assessed its mobility. Dendra2-tagged rbFOX1 was co-
transfected with a vector expressing either no repeats or expanded
CUG or CCUG repeats, then a nuclear spot of Dendra2-rbFOX1
was photoconverted from green to red and imaged every minute
to follow the nuclear diffusion of rbFOX1. Interestingly, photo-
converted Dendra2-rbFOX1 present in nuclear foci of CCUG
expressing cells moved away from the CCUG foci and diffused
freely in the nucleoplasm, albeit with a slightly slower kinetic
compared to rbFOX1 in control condition or with expanded
CUG repeats (Fig. 4a). As a control, photoconverted Dendra2-
MBNL1 diffuse freely in control cells but was immobilized in foci
of expanded CUG or CCUG repeats (Fig. 4b). These data suggest
that in contrast to MBNL1, rbFOX1 is not immobilized within
CCUG RNA foci.
In a second approach, we tested whether expanded CCUG
repeats would modify rbFOX1 splicing regulatory functions.
Alternative splicing of the human mitochondrial ATP synthase
gamma-subunit (ATP5C1 also named F1gamma) exon 9 minigene
is regulated by the rbFOX proteins39. However, overexpression of
expanded CCUG repeats does not modify ATP5C1 minigene
splicing (Fig. 4c). As a control, overexpression of expanded
CCUG repeats alters the splicing regulation of the insulin
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receptor (INSR) exon 11 minigene (Supplementary Fig. 4A). Of
interest, MBNL1 regulates INSR minigene splicing, but does not
modulate ATP5C1 minigene splicing (Fig. 4c and Supplementary
Fig. 4A). These results suggest that expression of expanded
CCUG repeats alters MBNL1 splicing regulatory function, but
does not modify rbFOX1 splicing activity. Importantly, identical
results were observed with endogenous alternative splicing events
regulated by the rbFOX proteins42. Namely, overexpression of
expanded CCUG repeats has no signiﬁcant effect on endogenous
Fmnl3 exon 26, Tbx3 exon 25, and Enah exon 11 A alternative
splicing (Fig. 4d and Supplementary Fig. 4B, 4C). We conﬁrmed
that overexpression or siRNA-mediated depletion of rbFox1
regulates Fmnl3, Tbx3 and Enah alternative splicing, while
expression or depletion of Mbnl1 has no effect (Fig. 4d and
Supplementary Fig. 4B, 4C). Western blotting indicated correct
siRNA-mediated depletion of rbFox1 and Mbnl1 proteins
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rbFOX1, MBNL1, 960 CUG repeats or 1000 CCUG repeats or with a siRNA directed against rbFox1 or Mbnl1. Lower panel, quantiﬁcation of exon 9 inclusion
of transfected ATP5C1 minigene. d Upper panel, RT-PCR analysis of endogenous Fmnl3 exon 26 alternative splicing from GFP-FACS sorted C2C12 cells
differentiated two days and co-transfected with a plasmid expressing eGFP and either with a plasmid expressing rbFOX1, MBNL1, 960 CUG repeats or
1000 CCUG repeats or with a siRNA directed against rbFox1 or Mbnl1. Lower panel, quantiﬁcation of Fmnl3 exon 26 inclusion. e–g RT-PCR analysis (left
panel) and quantiﬁcation (right panel) of alternative splicing of FMNL3, ENAH, and ECT2 performed on total RNA extracted from adult skeletal muscle of
control or DM2 individuals. Error bars indicate s.e.m. of three independent experiments. Student’s t-test, asterisk (*) indicates p < 0.5, asterisk (**)
indicates p < 0.01, asterisk (***) indicates p < 0.001
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(Supplementary Fig. 4D). As a further control, expression of
endogenous Mbnl1 is not altered upon overexpression or
depletion of rbFOX1 (Supplementary Fig. 4E).
Finally, we tested whether rbFOX-dependent alternative
splicing events were modiﬁed in skeletal muscle samples of
DM2 patients. RT-PCR analysis demonstrated that exon 26 of
FMNL3, exon 11 A of ENAH, and exon 25 of ECT2 do not display
any splicing abnormalities in muscle samples of individuals with
DM2 compared to control skeletal muscle samples (Fig. 4e, g). As
controls, alternative splicing of exons regulated by MBNL1,
namely exon 29 of CACNA1S (CAV1.1), exon AS1 of RYR1, exon
22 of ATP2A1 (SERCA), exon 7 of MBNL1 and exon 11 of LDB3
(CYPHER/ZASP), are all altered in DM2 muscle samples
(Supplementary Fig. 4F, 4G, 4H, 4I, 4J). Of interest, the extend
of splicing alterations in distal skeletal muscle samples is greater
in DM1 compared to DM2 (Supplementary Fig. 4F, 4G, 4H, 4I,
4J), which correlates with the greater impairment of distal muscle
in DM1 compared to DM2. These results indicate that, in
contrast to MBNL1, the splicing regulatory functions of the
rbFOX proteins are not altered by expression of expanded CCUG
repeats.
rbFOX compete the binding of MBNL1 to expanded CCUG
repeats. The binding of both MBNL1 and rbFOX1 to expanded
CCUG repeats questions whether these interactions are mutually
exclusive. In vitro, an excess of either rbFOX1 or rbFOX2 chases
MBNL1 from binding to CCUG repeats (Fig. 5a and supple-
mentary Fig. 5A). Conversely, an excess of MBNL1 competes
rbFOX1 binding to CCUG repeats (Fig. 5b). In DM2 muscle cell
cultures, overexpression of rbFOX1 reduces the quantity of
MBNL1 present within RNA foci of expanded CCUG repeats and
concomitantly increases the labeling of free diffuse MBNL1
(Fig. 5c). Inversely, shRNA-mediated depletion of rbFOX1
expression increases the localization of endogenous MBNL1
within CCUG RNA foci (Supplementary Fig. 5B). Consistent with
a mutually exclusive competition mechanism, overexpression of
MBNL1 partially displaces rbFOX1 from CCUG RNA foci in
DM2 muscle cells (Fig. 5d). As controls, we observed no dis-
placement of MBNL1 localization upon modulation of rbFOX1
expression in DM1 muscle cell cultures (Fig. 5c and Supple-
mentary Fig. 5C).
These results suggest that rbFOX1 competes with MBNL1 to
bind to CCUG RNA repeats. Nevertheless, it is possible that other
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mechanisms are at play. As noted previously44,50,51, overexpres-
sion of rbFOX1 inhibits inclusion of Mbnl1 exon 7 (Supplemen-
tary Fig. 5D). This 36 nts long exon is reported to modulate
MBNL1 self-dimerization52. However, this splicing change is
unlikely to contribute signiﬁcantly to MBNL1 reduced localiza-
tion within CCUG RNA foci upon rbFOX1 overexpression as in
the same conditions of rbFOX1 overexpression we observed no
changes in MBNL1 localization within CUG RNA foci in DM1
muscle cells (Fig. 5c and Supplementary Fig. 5C). Furthermore,
rbFOX1 overexpression neither changes MBNL1 nuclear/ cyto-
plasmic localization (Fig. 5c), nor MBNL1 global expression
(Supplementary Fig. 5E). Similarly, expressions of rbFOX1,
rbFOX2, MBNL1, and MBNL2 mRNAs are not altered in muscle
samples of individuals with DM2 compared to non-DM controls
or individuals with DM1 (Supplementary Fig. 5F).
A potential mechanism of competition requires that a sufﬁcient
quantity of endogenous rbFOX1 is expressed to prevail over
MBNL1. In human skeletal muscle, MBNL1 mRNA is expressed
at slightly higher level compared to rbFOX1 mRNA with 50 to 70
Transcripts Per Kilobase Million (TPM) for MBNL1 compared to
30 to 40 TPM for rbFOX1, while MBNL2 and rbFOX2 mRNAs
are expressed at similar levels (20 to 30 TPM)35,36. However,
western blotting analysis indicated that both rbFOX1 and
MBNL1 are expressed at similar levels in control or in DM2
adult human skeletal muscle samples (Supplementary Fig. 5G).
To avoid a bias due to antibody differences, recombinant puriﬁed
proteins were used as standards (Supplementary Fig. 5H). Thus, a
competition between MBNL1 and rbFOX1 is possible as these
proteins are expressed at comparable levels in human adult
skeletal muscle.
Expression of rbFOX1 corrects splicing alterations of CCUG
repeats. Titration of the MBNL proteins within CUG or CCUG
RNA foci leads to speciﬁc alternative splicing changes. Hence, we
tested whether the release of MBNL1 from CCUG RNA foci upon
rbFOX1 overexpression may correct splicing alterations typical of
myotonic dystrophy. Importantly, overexpression of rbFOX1 in
C2C12 muscle cells partly corrects splicing alterations of the
chloride channel (Clcn1) and of the cardiac troponin T (TNNT2)
minigenes induced by overexpression of expanded CCUG repeats
(Figs. 6a, b and Supplementary Fig. 6A). Inversely, siRNA-
mediated decreased expression of endogenous rbFox1 increases
the pathogenic effect of expanded CCUG repeats on Clcn1 and
TNNT2 minigene splicing (Supplementary Fig. 6B, 6C). In con-
trast, overexpression or decreased expression of rbFOX1 has no
correcting effect on Clcn1 and TNNT2 splicing changes induced
by expanded CUG repeats (Fig. 6a, b and Supplementary Fig. 6B
and 6C). As a positive control, expression of MBNL1 corrects
splicing alterations caused by either CUG or CCUG expanded
repeats (Fig. 6a, b). Note that MBNL1 regulates alternative spli-
cing of the Clcn1 and TNNT2 minigenes, while rbFOX1 has no
effect in absence of CCUG repeats (Fig. 6a, b). In support of a
splicing regulation directly modulated by MBNL1 but not by
rbFOX1, gel-shift experiments indicate that recombinant puriﬁed
MBNL1, but not rbFOX1, binds to Clcn1 and TNNT2 minigenes
(Supplementary Fig. 6D). As a further control, western blotting
indicates that overexpression of rbFOX1 does not modify endo-
genous Mbnl1 levels (Supplementary Fig. 6E).
Expression of rbFOX1 alleviates muscle atrophy. To test whe-
ther expression of rbFOX1 could rescue any deleterious pheno-
types caused by expression of expanded CCUG repeats, we
developed Drosophila models of DM1 and DM2 that overexpress
rbFOX1. Expression of uninterrupted expanded CTG or CCTG
repeats deleted of their natural DMPK or CNBP sequences were
targeted to ﬂy muscle through crossing UAS-CTG or UAS-CCTG
ﬂies with a Myosin heavy chain (Mhc)-GAL4 driver line. As noted
previously37, expression of expanded CUG or CCUG repeats
leads to muscle dysfunctions compared to a control GFP line or
to Drosophila lines carrying control (20×) CTG or CCTG repeats
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(Supplementary Fig. 7A). We then generated recombinant Dro-
sophila ﬂies expressing GFP-tagged rbFOX1 under the UAS
promoter and crossed these ﬂies with either DM1 or DM2 lines.
Importantly, overexpression of rbFOX1 fully rescues muscles
atrophy caused by expression of expanded CCUG repeats
(Fig. 7a). Two different independent Drosophila lines expressing
rbFOX1 were tested and gave comparable results (Fig. 7a).
Similarly, a second independent line expressing expanded CCUG
repeats was tested and shows identical muscle correction upon
overexpression of rbFOX1 (Supplementary Fig. 7B). Next, we
tested the effect of rbFOX1 in DM1 ﬂies. Interestingly, over-
expression of rbFOX1 does not suppress muscle atrophy in
Drosophila expressing expanded CUG repeats (Fig. 7b). As a
positive control, expression of MBNL1 fully corrects muscle
alterations in DM1 and DM2 ﬂies (Figs. 7a, b). Consistent with
correction of muscle atrophy, functional assays demonstrated that
overexpression of rbFOX1 rescues both ﬂying (Fig. 7c) and
climbing (Fig. 7d) defects caused by expression of expanded
CCUG repeats. This correction is speciﬁc, as overexpression of
rbFOX1 has no rescue effect in CUG expressing ﬂies (Figs. 7c, d).
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At the molecular level, titration of Drosophila Muscleblind
(Mbl) within CUG or CCUG RNA foci leads to speciﬁc mRNA
splicing alterations37. Importantly, overexpression of rbFOX1
corrects Fhos and Serca splicing alterations caused by expression
of expanded CCUG repeats, but has no correcting effect in DM1
ﬂies (Fig. 7e, f). As controls, Fhos and Serca alternative splicing
were not altered in GFP-tagged rbFOX1 ﬂies compared to control
GFP transgenic Drosophila (Supplementary Fig. 7C, 7D).
Furthermore, RNA FISH coupled to immunoﬂuorescence
indicated that rbFOX1 co-localizes with RNA foci of expanded
CCUG repeats, but not with RNA foci of expanded CUG repeats
(Supplementary Fig. 7E). Concomitant labeling of endogenous
Mbl showed that Mbl co-localizes with RNA foci of both
expanded CUG and CCUG repeats (Supplementary Fig. 7E).
Finally, we noted that the longevity of Drosophila expressing
either expanded CUG or CCUG repeats was reduced compared to
control or GFP-expressing ﬂies. Strikingly, overexpression of
rbFOX1 partly rescues the decreased lifespan of DM2 ﬂies, but
has no effect in DM1 ﬂies (Fig. 8a, b). Overall, these results
indicate that rbFOX1 can correct splicing alterations, muscle
atrophy, locomotor defects, as well as reduced lifespan in an
animal model of DM2.
Discussion
An RNA gain-of-function mechanism for myotonic dystrophy
predicts that an increased quantity or a higher number of
expanded CUG or CCUG repeats should lead to a greater titra-
tion of the MBNL RNA binding proteins, ultimately resulting in
increased severity of the disease. This model is consistent with the
increased number of CTG repeats, increased splicing alterations
and increased disease severity observed in congenital CDM1
compared to the adult-onset DM1 form23. However, this RNA
gain-of-function model is challenged by the milder severity of
DM2 compared to DM1, despite a higher number of expanded
repeats in DM2 compared to DM1. This paradox suggests the
existence of both common and distinct mechanisms involved in
the pathogenesis of DM1 and DM2. The most likely explanation
is that expanded CCUG repeats are inherently less pathogenic
due to their genomic localization. Indeed, expanded CCUG
repeats are located within the ﬁrst intron of the CNBP gene,
which presumably results in a lesser RNA stability and ultimately
a lesser expression of the CCUG repeats compared to the CUG
repeats embedded within the 3’UTR of the DMPK mRNA.
However, RNA FISH analyses revealed that CCUG RNA foci are
8 to 13 folds more intense than CUG RNA foci in skeletal muscle
tissues of individuals with myotonic dystrophy7, suggesting that
RNA foci are present at pathogenic levels in DM2. A second
mechanism possibly contributing to the increased toxicity of the
CUG repeats is the higher phosphorylation and expression of
CUGBP1 reported in DM1 hearts, especially in the most severely
affected individuals5. However, a higher expression of CUGBP1 is
also reported in DM2 samples53,54, although inconsistently33,55.
Thirdly, repeat-associated non-ATG (RAN) translation of CAG
repeats from antisense DMPK transcripts results in expression of
potentially toxic proteins in type 1 myotonic dystrophy56. How-
ever, RAN translation of sense CCUG and antisense CAGG
expanded repeats in brain samples of individuals with DM2 brain
is also reported57. It remains to be determined whether RAN
translation is deleterious or plays a protective role in respect to
MBNL1 titration in myotonic dystrophy56,57. Finally, a difference
of toxicity between expanded CUG and CCUG repeats based on a
difference in MBNL1 afﬁnity is unlikely as MBNL1 binds in vitro
to CCUG repeats with a slightly better afﬁnity compared to CUG
repeats58–60.
In the present work, we found that rbFOX1 binds to CCUG
repeats and that its overexpression partly reduces MBNL1 titra-
tion, splicing alterations and phenotype severity in cell and ani-
mal models of DM2. These data suggest a model where at the
time of CCUG repeats transcription, rbFOX proteins compete
with MBNL proteins for the binding to the nascent CCUG RNA
transcript, thus partially reducing MBNL1 titration (Fig. 8c, d). A
reduced titration of MBNL1 by expanded CCUG repeats is
consistent with the lesser splicing and differentiation defects
reported in DM2 muscle cell cultures compared to DM1 cells32–
34, and with the lesser alternative splicing changes that we
observed in DM2 distal muscles compared to DM1 distal muscle
samples. These data are also consistent with the absence of
expression of CG32062, the Drosophila ortholog of the rbFOX
proteins, in adult ﬂy skeletal muscles, which may explain the
absence of protection against expanded CCUG repeats in DM2 ﬂy
models. In conclusion, our data reinforce a model of RNA gain-
of-function for myotonic dystrophy as a lesser toxicity of the
CCUG expanded repeats can be partly explained by a lesser
titration of the causative MBNL RNA binding proteins.
This work raises several questions. First, rbFOX proteins reg-
ulate the alternative splicing of MBNL1 pre-mRNA44,50,51.
Indeed, overexpression of rbFOX1 in our cell systems changes
alternative splicing of MBNL1 exon 7, a 36 nts exon contributing
to MBNL1 dimerization52. In contrast, rbFOX1 does not alter
alternative splicing of Mbnl1 exons 3 and 5, which are 204 and 54
nts long exons regulating MBNL1 binding to RNA and nuclear
localization, respectively. Of interest, we observed no overt effect
of rbFOX1 overexpression on the global expression or the
nuclear/ cytoplasmic localization of MBNL1. Furthermore,
overexpression of rbFOX1 has a correcting splicing effect only in
CCUG expressing cells and not in control or in CUG expressing
cells. Thus, while we cannot formally exclude an indirect con-
tribution of MBNL1 exon 7 splicing change or other mechanisms
upon rbFOX1 overexpression, these results favor a model where
rbFOX1 overexpression partly competes MBNL1 away from
binding to CCUG repeats (Figs. 8c, d).
A second intriguing point is that rbFOX proteins are well
known to bind to the UGCAUGY RNA sequence. Here, we found
that rbFOX1 can also recognize CCUG expanded repeats.
Fig. 7 rbFOX1 alleviates the symptoms caused by expanded CCUG repeats. a Left panel, representative dorsoventral sections of resin-embedded adult
thoraces showing indirect ﬂight muscles (IFMs) of ﬂies expressing expanded CCUG repeats and GFP-tagged rbFOX1 or MBNL1. Right panel, IFM muscle
area quantiﬁcation. b As in a but with DM1 ﬂies expressing expanded CUG repeats. c Notched box plot showing the median and the distribution of average
landing height (cm) data from ﬂight assay of control, expanded CUG and expanded CCUG expressing ﬂies with or without expression of GFP-rbFOX1. The
horizontal lines within the boxes represent median values, whereas bottom and top edges of the boxes represent the 25th and 75th percentiles and bottom
and top whiskers reach the 10th and 90th percentiles, respectively. d Quantiﬁcation of climbing speed in mm/s of control, expanded CUG and expanded
CCUG expressing ﬂies with or without expression of GFP-rbFOX1. e Upper panel, RT-PCR analysis of endogenous Fhos exon 16 in ﬂies expressing expanded
CUG or CCUG repeats and GFP-rbFOX1. Lower panel, quantiﬁcation of Fhos exon 16 inclusion. f Quantiﬁcation of Serca exon 13 expression in ﬂies
expressing expanded CUG or CCUG repeats and GFP-rbFOX1. Detection of endogenous Rp49 gene expression was used for normalization. Expression of
transgenes in muscle was driven by Mhc-GAL4. Error bars indicate means ± s.e.m. of three to ﬁve independent experiments. Student’s t-test, asterisk (**)
indicates p < 0.01, asterisk (***) indicates p < 0.001
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However, rbFOX1 binding to a single UGCCUGC motif was
barely detectable compared to binding to the UGCAUGC RNA
motif. Thus, even if the structure of rbFOX1 can accommodate a
central cytosine instead of an adenosine, the binding of rbFOX1
to a single UGCCUGC motif is weak and likely not sufﬁcient to
regulate alternative splicing. In contrast, the extensive repetition
of that RNA motif in DM2 patients, in which up to 11,000 CCUG
repeats can be expressed, may compensate for the low afﬁnity of
rbFOX1 toward a unique UGCCUGC RNA motif. As a further
cautionary note, we tested direct binding of rbFOX1 to CCUG
repeats only in vitro and on expansions of limited size (10, 30 and
100 repeats). Thus, direct binding of rbFOX1 to large CCUG
expansions in individuals with DM2 will require a formal
demonstration, such as rbFOX1 CLIP experiments on human
DM2 tissue samples.
A third puzzling result is the absence of sequestration of
rbFOX1 within CCUG RNA foci. Indeed, splicing events regu-
lated by the rbFOX proteins are neither altered in CCUG-
expressing cells nor in skeletal muscle samples of individuals with
DM2. Similarly, photoconversion analysis indicated that rbFOX
proteins are not immobilized within RNA foci of expanded
CCUG repeats. These results are consistent with previous reports
demonstrating that a RNA binding protein can be enriched in
nuclear RNA foci without being immobilized within such struc-
ture61,62. These data conﬁrm that an image of co-localization is
not an evidence of immobilization and that functional seques-
tration should be experimentally tested. The mechanisms
underlying “liberty” of rbFOX1 but “captivity” of MBNL1 within
CCUG RNA foci are unclear. A possible explanation is that the
relative afﬁnity of rbFOX1 for its endogenous pre-mRNA targets,
which contain UGCAUGY RNA motifs, is higher compared to its
afﬁnity for expanded CCUG repeats. In contrast, MBNL1 pre-
sents a higher afﬁnity for CUG or CCUG repeats compared to its
normal pre-mRNA targets. Moreover, it is also possible that the
different RNA binding architectures between rbFOX and MBNL
proteins may play a role in modulating their sequestration, as
MBNL1 contains four zinc ﬁngers binding to four YGC RNA
motifs, while rbFOX1 binds to one UGCAUGY sequence through
its single RRM domain.
An additional argument against a functional titration of rbFOX
proteins by expanded CCUG repeats in DM2 is the study on
animal models and individuals with loss-of-function mutations of
rbFOX1 or rbFOX2. In mouse models, knockout for rbFox1 or
rbFox2 present severe skeletal muscle, heart and brain dysfunc-
tions51,63–66, which are different from the alterations observed in
myotonic dystrophy. In contrast, transgenic mice expressing
expanded CUG repeats present similar splicing alterations and
phenotypes than Mbnl1 and/ or Mbnl2 knockout
mice10,13,14,20,23,67. In humans, rbFOX1 binds to mRNAs that are
enriched in pathways involved in cortical neuronal
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proteins, resulting in their titration and sequestration in discrete nuclear RNA foci, ultimately resulting in alternative splicing changes that are inadequate to
adult physiology. d In myotonic dystrophy type 2, expanded CCUG repeats also titrate MBNL proteins, but with a lesser efﬁciency due to competition with
rbFOX proteins, which ultimately results in milder alternative splicing changes and milder symptoms compared to DM1
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development45,68, and mutations or deletions within the rbFOX1
gene have been identiﬁed in patients with neurological disorders
including epilepsy, schizophrenia, mental retardation and aut-
ism69–71, which are different from the symptoms observed in
DM2. Similarly, loss-of-function mutations in the rbFOX2 gene
are responsible for developmental cardiac alterations72–74, which
are different from the adult-onset progressive cardiac conduction
defects and arrhythmias observed in individuals with myotonic
dystrophy. Thus, human genetics and animal models argue
against a loss of rbFOX functions in myotonic dystrophy type 2.
Lastly, our study was restricted to skeletal muscle cells and
tissue samples. Hence, it remains to be determined the inﬂuence
of rbFOX proteins on the titration of MBNL1 and MBNL2 in
heart, as well as in neurons where rbFOX3 (NeuN) is highly
expressed. Similarly, whether the competition between rbFOX
and MBNL proteins may contribute to the absence of a congenital
form in DM2 remains to be tested. We also want to emphasize
that our study does not preclude that other mechanisms parti-
cipate to the lesser severity of DM2.
In conclusion, these results conﬁrm that the sequestration of
MBNL1 within CUG or CCUG RNA foci is a binding titration
that can be reversed through competition with antisense oligo-
nucleotides75, small molecules76,77, or RNA binding proteins24.
These various approaches may hopefully open some route for
therapeutic approaches in myotonic dystrophy.
Methods
Drosophila genetics and functional analysis. Mhc-GAL4 and UAS-MBNL1 lines
were previously described78. UAS-(CTG)20x , UAS-(CTG)250x , UAS-(CCTG)20x
and UAS-(CCTG)1000x transgenic lines were previously described37. The line UAS-
rbFOX1-GFP was generated by injecting the plasmid into w1118 embryos by
BestGene Inc. For simultaneous expression of rbFOX1 or MBNL1 and CTG or
CCTG expanded repeats, we generated recombinant ﬂies UAS-rbFOX1 UAS-
repeats and UAS-MBNL1 UAS-repeats. We expressed UAS-GFP transgene
simultaneously with the expanded repeats as a control of transgene dosage for
comparisons in the rescue experiments. Expression of the transgenes in muscle was
achieved by crossing the recombinants ﬂies toMhc-GAL4. All ﬂies were maintained
at 25 °C with standard food. Longevity assays, ﬂying assays, RNA extraction, RT-
PCR and qRT-PCR, as well as processing of Drosophila tissues for ﬂuorescent and
histological assessments were performed as described37. RNA foci detection was
performed using either CAG8x- or CAGG8x-Cy3 DNA oligonucleotide probes
(Sigma). Rabbit anti-GFP (Roche) and sheep-anti-Mbl antibodies were used to
detect rbFOX1-GFP and endogenous Mbl expression in ﬂy muscle, respectively.
Groups of ten 5-day-old males were transferred into vials of 1.5 cm in diameter and
25 cm in height and were tested for climbing velocity after a period of 24 h without
anesthesia. The height reached from the bottom of the vial by each ﬂy in a period of
10 s was recorded with a camera. For each genotype, approximately 30 ﬂies were
tested. The results show the mean speed in mm/s.
Plasmids and constructions. Interrupted 960 CTG repeats, deprived of DMPK
sequence, were subcloned from the DT960 plasmid9 into pCDNA3.1. Pure CTG
and CCTG expanded repeats were generated by PCR ampliﬁcation of self-priming
single-stranded CTG and CAG or CCTG and CAGG oligonucleotides as descri-
bed79. Synthesized DNA duplexes were electrophoresed, size fractionated, puriﬁed
by DNA gel extraction kit (Qiagen), 5’-phosphorylated with T4 polynucleotide
kinase and cloned into the EcoRV site of pcDNA3.1 or pUAS plasmids. The
recombinant plasmids containing uninterrupted stretches of 250 CTG or 1,000
CCTG repeats were ampliﬁed in STBL3 (Invitrogen) E. coli strain at 20 °C. Plasmid
DNA was puriﬁed using Qiagen plasmid DNA puriﬁcation kit and sequenced from
either end to ensure sequence integrity of the clones. MBNL1 and rbFOX1 cDNAs
are encoding full-length muscle isoform proteins with their respective Nuclear
Localization Signal (NLS), corresponding to MBNL1 42 kDa isoform (Accession #
NM_207293.1; transcript variant #3) that includes the exon linker between the four
zinc ﬁngers and the exon 6 of 54 nts encoding part of MBNL1 NLS, and the
rbFOX1 transcript variant #2 (Accession # NM_145892.2) encoding the full RRM,
the muscle M43 exon and its FAPY end involved in nuclear localization. MBNL1
and rbFOX1 cDNAs were cloned in frame downstream of the GST tag in pET28
vector, downstream of either the eGFP-tag or of the Flag-tag in classic eukaryotic
or Drosophila expression vectors. Concerning recombinant proteins, truncated
cDNA of MBNL1 (MBNL1Δ101 containing residues 1 to 253) contains the full N-
terminal RNA binding domain of MBNL1 but lacks its C-terminal part that is
insoluble and impairs MBNL1 expression and puriﬁcation in bacteria. CTG
(#63087), CCTG (#63088), rbFOX1 (#63085) and MBNL1 (#61277) expression
plasmids have been deposited on Addgene.
Patient and cell samples. Muscle biopsies and primary human myoblast cells
originating from muscle needle biopsies of six non-DM control individuals, seven
individuals with DM1 and seven individuals with DM2 were described pre-
viously18,27,30,32–34,55. All skeletal muscle biopsies, taken either from the anterior
tibial or gastrocnemius muscles were performed for diagnostic purpose and were
obtained from patients genetically conﬁrmed heterozygous for the DM1 or DM2
expansion, as well as from control individuals. All studies were done with the
approval of the Institutional Review Board of the Ludwig-Maximilians University
in Munich, of the Neuromuscular Research Center of the Tampere University
Hospital, of the IRCCS Policlinico San Donato and of the Toneyama National
Hospital. Informed consent was obtained from all human participants.
nanoLC-MS/MS analysis. One milligram of nuclear proteins extracted from
mouse brain or C2C12 muscle cells differentiated four days were passed over
synthetic biotinylated CCUG30x or CUG30x RNA (30 nmoles, Thermo Scientiﬁc)
bound to streptavidin coated magnetic beads (Dynabeads M-280 streptavidin,
Invitrogen) in the presence of 20 mM Hepes, 300 mM NaCl, 2 mM MgCl2, 0.01%
NP40, 1 mM DTT and protease inhibitor (PIC, Roche). The magnetic beads with
immobilized RNA and their bound proteins were washed three times with the
binding buffer and bound proteins were eluted by boiling 3 min in sample buffer
prior to 4–12% SDS-PAGE (NuPAGE 4–12% bis-Tris Gel, Invitrogen) separation
and silver staining (SilverQuest, Invitrogen). Protein bands were excised from the
gel, digested and identiﬁed using NanoESI_Ion Trap (LTQ XL Thermo Fisher
Scientiﬁc).
Recombinant protein production and puriﬁcation. E. coli BL21(RIL) pRARE
competent cells (Invitrogen) were transformed with pet28a-GST-rbFOX1, pet28a-
GST-rbFOX2 or pet28a-GST-MBNL1Δ101, grown at 30 °C in 400 ml of LB medium
supplemented with Kanamycin until an OD600 of 0.5, then 0.5 mM IPTG was
added and the culture was further incubated 4 h at 30 °C. Harvested cells were
sonicated in 50 mM Tris-Cl pH 7.5, 300 mM NaCl, 5% glycerol, 1 mM DTT, 5 mM
EDTA, centrifuged 20 min at 20000 g and recombinant GST-tagged proteins were
puriﬁed using the GST-BindTM Kit (Novagen).
In vitro RNA transcription. Plasmids were linearized by EcoR1 restriction and 100
ng were transcribed using T7 transcription kit (Ambion) in presence of 1 µl of
[αP32]-UTP (Perkin Elmer), analyzed on 8% denaturing polyacrylamide and
quantiﬁed with LS-6500 counter (Beckman). Non-labeled transcripts were syn-
thesized using the Megascript T7 kit (Ambion). After transcription, 1 unit of
DNase I (Invitrogen, Carlsbad, CA) was added, and the sample was incubated for
additional 30 min at 37 °C. Transcribed RNAs were then puriﬁed by micro Bio-
Spin 6 chromatography columns (Bio-rad) according to the manufacturer’s
instructions. The sizes of RNAs were checked by gel electrophoresis on a dena-
turing 6% polyacrylamide gel.
Gel shift assays. 10 pM (3000 CPM) of labeled RNA was incubated at 90 °C for 5
min in binding buffer (BB, 0.75 mM MgCl2, 50 mM Tris-HCl (pH 7.0), 75 mM
NaCl, 37.5 mM KCl, 5.25 mM DTT, 0.1 mg/mL BSA, 0.1 mg/mL Bulk tRNA) and
allowed to cool to room temperature. After cooling, RNAsin was added to a ﬁnal
concentration of 0.4 U/μl. GST-MBNL1Δ101, GST-rbFOX1 or GST-rbFOX2 were
then added and the mixture was incubated on ice for 20 min. The solution mixture
was loaded onto a non-denaturing 6.0% (w/v) polyacrylamide gel (acrylamide/
bisacrylamide, 40:1, w/w) containing 0.5 × TBE (1 × TBE is 90 mM Tris-base, 89
mM Boric acid and 2 mM EDTA (pH 8.0)), which had been pre-electrophoresed at
110 V for 20 min. at 4 °C. The gel was electrophoresed at 110 V at 4 °C for 3 h, then
dried and exposed to a phosphorimager screen and imaged using a Typhoon 9410.
The data were ﬁt to the following equation: y=min+ ((max-min)/(1+ (x/IC50)-
HillSlope)) where y is the percentage of RNA bound, x is the concentration of
protein, min and max are the minimum and maximum percentage of RNA bound
to MBNL1 or rbFOX1 or rbFOX2 (0-100%) and IC50 is the concentration where
50% of maximum binding is achieved.
UV-crosslinking assays. Twenty microgram of nuclear extract from C2C12
muscle cells differentiated four days or 0.5 to 1 µg of recombinant GST-
MBNL1Δ101, GST-rbFOX1 or GST-rbFOX2 protein were incubated with 100 pM
(30,000 CPM) of in vitro transcribed RNAs containing either 30 CUG or 30 CCUG
repeats of uniformly [αP32] internally labeled, in 15 µl of 100 mM NaCl, 20 mM
Hepes, 8 mM MgCl2, 0.1 mg/ml BSA, 0.1 mg/ml heparin and 0.5 mM DTT during
15 min at 30 °C. Reactions were transferred on paraﬁlm and irradiated 5 min, on
ice, at 2.5 cm of a UV lamp (Vilberloumat VL-100C). 1 µg of RNase A1 was added
and incubated 30 min at 37 °C. RNA-protein complexes were resolved on 10%
SDS-PAGE, coomassie labeled and analyzed using BAS-MS imaging plate (Fuji)
and Typhoon 8600 imager (Molecular Dynamics).
NMR and in silico energy minimization. 1H-15N HSQC spectra were recorded
using recombinant expressed 15N-labeled rbFox1-RRM (residues 108–216) on a
Bruker Avance III 700MHz spectrometer. All experiments were performed at 310
K in buffer containing 20 mM NaCl and 20 mM NaH2PO4 at pH 6.5 and 5% D2O.
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Spectra were processed in Topspin 3.0 and visualized using Sparky 3.114. Initial
coordinates were obtained by in silico mutation in PyMol using rbFox1-RRM
bound to UGCAUGU (pdb code 2ERR) established previously49. Subsequent
energy minimization was performed in AMBER 12. An unrestraint minimization
was applied using the conjugate gradient method (XMIN) with a 0.01 convergence
criterion for the root-mean-square.
Cell cultures, transfections and transduction. C2C12 cells were grown in
DMEM, 1 g/1 glucose, 20% fetal calf serum and gentamycin at 37 °C, 5% (v/v) CO2.
C2C12 were transfected with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions with control plasmid or plasmid expressing 1,000
CCUG repeats. Six hours after transfection, the medium was removed and cells
were differentiated two days in DMEM, 1 g/1 glucose, 2% fetal calf serum, insulin
10 µg/ml and gentamycin medium before RNA-FISH coupled to immuno-
ﬂuorescence. For endogenous splicing assays, C2C12 cells were co-transfected
using Lipofectamine 2000 (Invitrogen) with a plasmid expressing GFP and a
plasmid expressing either rbFOX1, MBNL1, 960 CUG repeats or 1,000 CCUG
repeats. GFP positive cells were isolated two days after differentiation by using
FACS Diva. For minigene splicing assays, C2C12 cells were co-transfected using
Lipofectamine 2000 (Invitrogen) with a plasmid expressing the INSR or F1gama
minigene and a plasmid expressing rbFOX1, MBNL1, 960 CUG repeats or 1000
CCUG repeats and differentiated 2 days before analysis. siRNA against rbFox1 or
Mbnl1 were transfected by using RNAimax (Invitrogen) according to manu-
facturer’s instruction. Primary human myoblast cells originate from muscle
biopsies of genetically conﬁrmed DM1 and DM2 patients. Myoblast cells were
maintained at 37 °C with 10% CO2 in skeletal muscle cell basal media with sup-
plements (PromoCell, Heidelberg, Germany) and 10% fetal calf serum. For myo-
blast differentiation, cells were maintained in DMEM with 2% fetal calf serum. For
competition experiments, primary culture of muscle cells from DM2 patient was
grown in DMEM, 1 g/1 glucose, medium 199 (4:1), 20% fetal calf serum and
gentamycin at 37 °C, 5% (v/v) CO2 and transfected with a control pCDNA3.1
plasmid or a plasmid expressing FLAG tagged rbFOX1 according to Lipofectamine
2000 manufacturer’s instructions. Cells were differentiated in DMEM, 1 g/1
glucose, medium 199 (4:1), 2% fetal calf serum, insulin 10 µg/ml and gentamycin
ﬁve days before analyze. Transductions at a MOI of 1000 with recombinant
adenovirus expressing a shRNA either directed against the luciferase or against
rbFOX1 or MBNL1 were done on primary culture of muscle cells from DM patient
differentiated two days. Medium was replaced 24 h after infection, and cells were
analyzed 48 h after infection.
Photoconversion analysis. Live imaging was performed on a Nikon TiE inverted
microscope (Nikon Instruments, Japan) equipped with a Tokai incubation cham-
ber (Tokai Hit, Japan). We used a Nikon 100 × Apo TIRF NA 1,49 objective, image
acquisition was done with a Yokogawa CSU-X1 spinning disk (Yokogawa Electric
Corporation, Japan) coupled to a Photometrics Evolve 512 camera (Photometrics,
Tucson, USA). A foci of Dendra2 tagged protein was photoconverted at 405 nm
with a Roper Sientiﬁc ILas2 FRAP unit using Frap on Fly mode. In absence of foci,
namely MBNL1 or rBFOX1 in control conditions or rbFOX1 with expanded CUG
repeats, a 1 µm diameter spot of Dendra2-tagged protein was randomly chosen
within the nucleoplasm and photoconverted. Dendra2-MBNL1 or Dendra2-
rbFOX1 was imaged every thirty seconds after photoconversion with a 561 nm
laser. The system was controlled by Metamorph software. For image analysis, mean
intensity of the aggregate was measured over time using Fiji, and background and
photobleaching corrections were applied.
RNA FISH combined with immunoﬂuorescence. Frozen human muscle sections
were incubated in PBS 1× during 10 min before RNA FISH. Glass coverslips
containing plated cells or human sections treated as described above were ﬁxed in
PFA 4% during 15 min and washed two times with PBS. The coverslips or slides
were incubated for 10 min in PBS plus 0.5% Triton X-100 and washed three times
with PBS before pre-hybridization in 40% DMSO, 40% formamide, 10% BSA (10
mg/ml), 2× SCC for 30 min. The coverslips or slides were hybridized for 2 h in 40%
formamide, 10% DMSO, 2× SCC, 2 mM vanadyl ribonucleoside, 60 μg/ml tRNA,
30 μg/ml BSA plus 0.75 μg CAG8x- or CAGG8x-Cy3 DNA oligonucleotide probe
(Sigma). Following FISH, the coverslips or slide were washed twice successively in
2 × SCC/50% formamide, in 2× SCC and in PBS. The coverslips or slides were
incubated 2 h with primary polyclonal antibody against MBNL1 (1/100 dilution,
gift of Prof. Charles Thornton) and monoclonal rbFOX1 (1/100 dilution, gift of
Prof. Doug Black) or monoclonal rbFOX2 (Abcam ab57154). Slides or coverslips
were washed twice with PBS before incubation with a goat anti-rabbit secondary
antibody conjugated with Alexa-Fluor 488 (1/500 dilution; Fisher Scientiﬁc SA)
and donkey anti mouse secondary antibody conjugated with Cy5 (1/500 dilution;
Interchim SA) for 60 min; incubated for 10 min in 2 × SCC/DAPI (1/10 000
dilution) and rinsed twice in 2 × SSC before mounting in Pro-Long media
(Molecular Probes). Slides were examined using a ﬂuorescence microscope
(Leica).
Western blotting analyses. Proteins were denatured 3 min at 95 °C, separated on
4–12% SDS-PAGE gel (Invitrogen), transferred on nitrocellulose membranes
(Whatman Protan), blocked with 5% non-fat dry milk (NFM) in Tris Buffer Saline
buffer (TBS), incubated with rabbit anti-rbFOX1 (Abcam ab83574), anti-MBNL1
(gift of Prof. Glenn Morris) in TBS-5% NFM, washed 3 times and incubated with
anti-rabbit or -mouse Peroxidase antibody (Jackson Immunoresearch, 1:3000) 1 h
in TBS-5% NFM, followed by autoradiography using the ECL chemoluminescence
system (ThermoFisher).
RT-PCR analyses. Total RNA from cells or patient muscle was isolated by
TriReagent (Molecular Research Center). cDNAs were generated using the Tran-
scriptor High Fidelity cDNA synthesis kit (Roche Diagnostics) for quantiﬁcation of
mRNAs. PCR was performed with Taq polymerase (Roche), one denaturation step
at 94 °C for 2 min, 30 cycles of ampliﬁcation 94 °C for 1 min, 60 °C for 1 min, 72 °C
for 2 min and a ﬁnal step at 72 °C for 5 min using the primer described below. The
PCR products were precipitated, analyzed by electrophoresis on a 6.5% poly-
acrylamide gel, stained with ethidium bromide and quantiﬁed with a Typhoon
scanner.
Oligonucleotides.
MINIGENE SPLICING–RT-PCR
INSR-FW TAATACGACTCACTATAGGGC
INSR-REV GCTGCAATAAACAAGTTCTGC
ATP5C1-FW GTCATCACAAAAGAGTTGATTG
ATP5C1-REV CACTGCATTCTAGTTGTGGTTTGT
ENDOGENE SPLICING–RT-PCR
Human TBX3-FW CACGGTAGAACGAGGCATTT
Human TBX3-REV AGACGGGGCTGATTAACCTT
Human ENAH-FW TGCTTCAGCCTGTCATAGTCA
Human ENAH-REV TGGCAGCAAGTCACCTGTTA
Human ECT2-FW CAGAATCCTGAAAGTCCGTGA
Human ECT2-REV TTGGTTCAAGAAGCTGGAAAA
Human CACNA1S-FW AGGAGGGTTCGCACTCCTTCT
Human CACNA1S-REV GCTACTTTGGAGACCCCTGGA
Human RYR1-FW GACAACAAAAGCAAAATGGC
Human RYR1-REV CTTGGTGCGTTCCTGGTCCG
Human ATP2A1-FW CCATCGGTGCATGCCGAACGAGC
Human ATP2A1-REV CTCGTGGGCTCCATCTGCCTGTCC
Human LDB3-FW GCAAGACCCTGATGAAGAAGCTC
Human LDB3-REV GACAGAAGGCCGGATGCTG
Human MBNL1-FW GCTGCCCAATACCAGGTCAAC
Human MBNL1-REV TGGTGGGAGAAATGCTGTATG
ENDOGENE EXPRESSION–qRT-PCR
Human MBNL1 FW CATTTGCAAGCCAAGATCAA
Human MBNL1 REV AACTGGTGGGAGAAATGCTG
Human MBNL2 FW GCCCAGGCAGATGCAATTTAT
Human MBNL2 REV GTGGACTTCCGGGAACAATA
Human rbFOX1 FW CCCGAGCACACATTAAACCT
Human rbFOX1 REV CGGAACCTCAAGGGGATATT
Human rbFOX2 FW AAGCCCAGTAGTTGGAGCTG
Human rbFOX2 REV CAAATGGGCTCCTCTGAAAG
Human CNBP FW TGCTATAACTGCGGTAGAGGT
Human CNBP REV TTGAATGTGTCCGAATTCTCC
Human DMPK FW CATGAACAAGTGGGACATGC
Human DMPK REV CAATCTCCGCCAGGTAGAAG
Mouse Mbnl1 FW CGGGACACAAAATGGCTAAC
Mouse Mbnl1 REV TTGCAGTTCTCTCTGGAGCA
Mouse Mbnl2 FW TTTTCCCACATCCTCCAAAG
Mouse Mbnl2 REV GAATGTGTCAGCAAGCAGGA
Mouse rbFox1 FW GCATAGAAGTCGGGGCTGTA
Mouse rbFox1 REV GAGGGAGAAATTGCACGGTA
Mouse rbFox2 FW AACCAGGAGCCAACAACAAC
Mouse rbFox2 REV TGTCTGTGCTCCACCTTCTG
Mouse Cnbp FW TCACCTTGGTGCAGTCTTTTT
Mouse Cnbp REV ACTGCAAGGAGCCCAAGAG
Mouse Dmpk FW AGCGGTGGTGAAGATGAAAC
Mouse Dmpk REV AGTGCAGCTGTGTGATCCAG
RPLPO FW GAAGGTGTAATCCGTCTCCA
RPLPO REV GAAGTCACTGTGCCAGCCCA
DROSOPHILA TRANSGENES EXPRESSION - RT-PCR and qRT-
PCR
SV40 FW GGAAAGTCCTTGGGGTCTTC
SV40 REV GGAACTGATGAATGGGAGCA
Drosophila RP49 FW ATGACCATCCGCCCCAGCATAC
Drosophila RP49 REV ATGTGGCGGGTGCGCTTGTTC
Drosophila Fhos FWD GTCATGGAGTCGAGCAGTGA
Drosophila Fhos REV TGTGATGCGGGTATCTACGA
Drosophila Serca FWD GCAGATGTTCCTGATGTCG
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Drosophila Serca REV CGTCCTCCTTCACATTCAC
GEL SHIFT SEQUENCES
Vector sequence is indicated in lowercase, sequence of interest is indicated in
uppercase.
UGCAUGC: gggagacccaagctggctagcgtttaaacttaagcttTGCATGCg
UGCCUGC: gggagacccaagctggctagcgtttaaacttaagcttTGCCTGCg
(CUG)Nx: gggagacccaagctggctagcgtttaaacttaagctt (CTG)Nx g
(CCUG)Nx: gggagacccaagctggctagcgtttaaacttaagctt (CCTG)Nx g
Human INSR
gggagacccaagctggctagcgtttaaacttaagcttGTGCGACCCCTGGTGCCTGCTCCGCG
CAGGGCCGGCGGCGTGCCAGGCAGATGCCTCGGAGAACCCAGGGGTTT
CTGTGGCTTTTTGCATGCGGCGGGCAGCTGTGCTg
Human BIN1
gggagacccaagctggctagcgtttaaacttaagcttTACCGGCAGTGAGTGCTGCGGAGGGG
CGCAGAGGCCCGCGCCCTGGCTGGCCCTGTGCATGCGCCTTGCGCCCTG
CTCCCAGGTGCCACTAACCCGTAATCTGGCTCTGTGTGCAGTGCTGCCC
GGCAGGGCTGTCGTGTGCGTGTTGGGTGGGAAg
Human TNNT2
gggagacccaagctggctagcgtttaaacttaagcttAACCACTGCGCTGGGTGGCTGCTCCTG
CCGCGGGCTCTCTGCTCCCAGACTAACCTGTCTCGCTTTTCCCCTCCGCT
GCGGCCACTCCCTGAACCTCAGAAGAGGAGGACTGGAGAGAGGACGAA
GACGGTAGTACAGCCTTTCCTTCTGTGGTGCTTTCTGCTGCCTGCTGTCC
CAAGTGCAGCCTCCTTGTCCAGGGGCCCTGTTCTGGGGGCTGGGGGGT
GTGAGTAGGCGGCAGGGACGGAGTGGGTCAGTCGTTTCCTg
Mouse Clcn1
gggagacccaagctggctagcgtttaaacttaagcttTCCATGTTTCCTCCTGTGCTGCCCCCG
TTCTTCTGTGCTTCCTGACACCCATCCACCTGGTTTACATACCACCTGTC
TGTCCCCCTCTGCCACCTGCCTCGCCCGTCGTGCTTCTCTGTTGCAGACC
GTGCCTGGGCAGCTTGATCTCCTGGTGCCAGCCTGTGCAGTGGGCGTGG
GATGCTACTTTGCAGCCCCTGATGGAGGCAAGTTTCACTTCCTCCCTAC
CTTGGTTGCCTGAGCCAGACTTGGAGGGGTGGTTTGTGTCTGCTGTGG
CTTTGGGGTTGAGGGGCCATGCTCACTGAAGGAACTTATGGGTGGGCg
Data availability. rbFOX1 RRM binding to the UGCCUGC RNA sequence was
computed using rbFOX1 RRM bound to the UGCAUGC sequence, which coor-
dinates have been previously deposited to the Protein Data Bank under the 2ERR
accession code49. The data that support the ﬁndings of this study are available
within the article and its supplementary information ﬁles or from the corre-
sponding authors on reasonable request.
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